Tafluposide, formerly known as F-11782, is a DNA topoisomerase inhibitor potentially for the treatment of solid tumors. Tafluposide induces delayed, but extensive, DNA strand breaks. Tafluposide showed significant cytotoxicity against cells derived from either hematological or solid tumors, with a marked inter-patient variation. There was no significant difference between the effect of tafluposide in samples from untreated or previously treated patients. Whilst tafluposide appeared to show weak cross-resistance with the topoisomerase II inhibitor etoposide in acute myeloid leukemia, there did not appear to be any correlation with the effect of the topoisomerase I inhibitor topotecan in either hematological or solid malignancies. References: Kluza J, Mazinghien R, Irwin H, Hartley JA, Bailly C. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide. Anticancer Drugs. 2006 Feb;17(2):155-64. PubMed PMID: 16428933.

纯度：≥98%

CAS：179067-42-6